The tweet was deleted by the author.
But we saved everything 🙂.
Foghorn Therapeutics issued an update for the third quarter of 2026, citing continued progress across its oncology and immunology and inflammation pipeline.
Key areas of advancement include its oral inflammatory bowel disease program, development of a selective EP300 degrader, and exploration of a novel induced-proximity approach.
View post on X Loading...